Navigation Links
Pharmaxis Announces Placement of $47 Million and Share Purchase Plan
Date:6/3/2009

SYDNEY, June 3 /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS, Nasdaq: PXSL) today announced that it had raised A$47 million through a placement to Australian and international institutions and professional investors. The placement strengthens the company's balance sheet as Pharmaxis moves toward the European and U.S. commercial launch of its product Bronchitol for cystic fibrosis.

Pharmaxis will issue 20 million new fully paid ordinary shares at A$2.35 per share, a 10.6% discount to Pharmaxis' last closing price on 1 June 2009 and an 8.5% discount to the volume weighted average share price over the past 30 days. The shares to be issued will rank equally with existing ordinary shares in the capital of the company.

The placement has been managed by Wilson HTM Corporate Finance Limited and closed oversubscribed. Settlement of the placement is scheduled to take place on 10 June 2009.

A share purchase plan will be offered to all Australian and New Zealand shareholders who hold shares as at 7.00pm on 1 June 2009 and will afford the opportunity to purchase up to $5,000 worth of fully paid ordinary shares at the placement price of A$2.35, without brokerage or transaction costs. The share purchase plan offer opens on 10 June and closes on 24 June 2009. The share purchase plan will be capped at A$10 million.

"The proceeds from this offering are principally to be used for the commercial launch of Bronchitol for cystic fibrosis in both Europe and the U.S. This placement means Pharmaxis can take an important additional step in building a profitable, international, pharmaceutical business. We are very pleased with the support from the participating institutions and look forward to bringing Bronchitol to the world," said Pharmaxis Chief Executive Officer Dr Alan Robertson.

Forward-Lo
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. New Pharmaxis Board Appointment
2. Pharmaxis Investor Conference Call
3. Pharmaxis Appoints French Distributor for Aridol(TM)
4. Pharmaxis Builds Senior Management Team
5. Pharmaxis Investor Conference Call
6. Pharmaxis Aridol Approved for Sale in Switzerland
7. Pharmaxis Investor Conference Call
8. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
9. New Pharmaxis Board Appointment
10. Pharmaxis Aridol Authorised for Sale in Germany
11. Pharmaxis First Steps into China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... and synthetic processes prefer to settle into equilibriuma ... is within the realm of non-equilibrium conditions where ... in energy and phases, such as temperature fluctuations, ... humans to regulate their body temperature, airplanes to ... activity. , But even though these conditions ...
(Date:7/24/2014)... Your cell phone may stay ... battery storage capacity. , New research indicates that ... created at Lawrence Livermore National Laboratory ... carbon components will perform as electrodes. , The ... need for higher-performance batteries. Several key characteristics of ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Three companies ... semi-finalists in Livestrong’s Big C Competition. Out of 700 ... each headed to the semi-final round. In this round ... three-month accelerator program, complete with mentoring from thought-leaders and ... As part of the angelMD commitment to the Livestrong ...
(Date:7/24/2014)... July 24, 2014 WIRB-Copernicus Group ® ... and ethical review services for clinical research, announced ... a division of Richmond, VA ... biosafety and biosecurity consulting firm in ... WCG,s biosafety division – WCG Biosafety™ – will ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... in Pharmaceutical Thin Film,Technology -, WARREN, N.J., ... specializing in quick dissolving thin film pharmaceutical products,today ... No. 7,425,292 from the,United States Patent and Trademark ... to issue on September 16, 2008, relates,to the ...
... Calif., Sept. 11 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... fourth quarter and year-end financial results on September,16, 2008., ... discuss its financial results.,Details for the fiscal year-end call ... 16, 2008 -- Time: 10:30 a.m. ET, 9:30 ...
... Deliver Yield Benefits and Value to Farmers, LONDON, ... a significant growth opportunity in continuing to create more ... and,breeding, leading to more than doubling the company,s 2007,s ... biotechnology, will,tell investors. Padgette will deliver his remarks as ...
Cached Biology Technology:MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process 2MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process 3Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit 2Monsanto Sees Growing Opportunity for Biotech Traits Globally 2Monsanto Sees Growing Opportunity for Biotech Traits Globally 3Monsanto Sees Growing Opportunity for Biotech Traits Globally 4
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
(Date:7/24/2014)... two factors that characterize sustainable university and college ... qualified physics teachers. Specifically, one or more faculty ... in combination with institutional motivation and commitment can ... Engineering and Math (STEM) teacher shortages are especially ... way for institutions seeking to increase the number ...
(Date:7/24/2014)... own microbial terroir, meaning the microbial populations found on ... product, creating the final flavor according to research published ... Environmental Microbiology . This is the first time investigators ... , Many sake makers inoculate with both bacteria ... the University of California, Davis, but he and his ...
Breaking Biology News(10 mins):NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Creating sustainable STEM teacher preparation programs 2The microbes make the sake brewery 2
... studied interactions between the loggerhead turtle ( Caretta caretta ) ... water surface, mass beachings, and the effects of climate change ... marine species without causing economic losses for fishermen, the scientists ... carried out by night and in areas more than 35 ...
... EAST LANSING, Mich. A team of Michigan State ... created have uncovered the inner workings of a ... develop new medicines or understand how enzymes repair DNA. ... bacterial enzyme that is important in metabolism. Enzymes in ...
... Copenhagen summit to draft a legally binding agreement on the ... that we will see further rapid changes in the global ... the planet,s most vulnerable species at this time of unprecedented ... on 26 February 2010 in the Journal of Experimental ...
Cached Biology News:How can accidental captures of loggerhead turtles be reduced? 2MSU scientists unlock key enzyme using newly created 'cool' method 2Tackling the challenges of survival in a changing world 2Tackling the challenges of survival in a changing world 3
... involves the optimization of immunostaining. ... of the primary antibody, selection ... (e.g. Alk. Phos., HRP, fluorescence, ... detection, evaluation by light or ...
Request Info...
... 9001:2000 Certified USDA Research Registered OLAW Assured ... Training AALAS Certified Technicians Documentation ... Documentation Upon Request Focus CRP ... all your custom immunology service needs. ...
Request Info...
Biology Products: